Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 1.00 |
| ▸ | GAA | P10253 | 6/20 | 1.00 |
| ▸ | CRHBP | P24387 | 1/20 | 0.97 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.75 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.71 |
| ▸ | HTT | P42858 | 2/20 | 0.71 |
| ▸ | HPGD | P15428 | 2/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.57 |
| ▸ | ERN1 | O75460 | 1/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29432837 | 1.00 | MAPT (1.00) | MAPTKDM4EALDH1A1GAACRHBP | |
| SCHEMBL30294879 | 0.98 | CRHBP (1.00) | MAPTKDM4EALDH1A1GAACRHBP | |
| SCHEMBL13700903 | 0.98 | CRHBP (1.00) | MAPTKDM4EALDH1A1GAACRHBP | |
| SCHEMBL23802529 | 0.86 | MAPT (0.75) | MAPTKDM4EALDH1A1GAACRHBP | |
| SCHEMBL30616755 | 0.86 | MAPT (0.75) | MAPTKDM4EALDH1A1GAACRHBP | |
| SCHEMBL6057649 | 0.86 | KDM4E (1.00) | MAPTKDM4EALDH1A1GAACRHBP | |
| SCHEMBL31618184 | 0.84 | KDM4E (0.72) | MAPTKDM4EALDH1A1GAACRHBP | |
| SCHEMBL15347439 | 0.83 | KDM4E (1.00) | MAPTKDM4EALDH1A1GAACRHBP | |
| SCHEMBL13969347 | 0.81 | KDM4E (0.85) | MAPTKDM4EALDH1A1GAACRHBP | |
| SCHEMBL31618209 | 0.81 | KDM4E (0.68) | MAPTKDM4EALDH1A1GAACRHBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117024364-A | Pyrazole ionic liquid and method for catalyzing Betti reaction by using pyrazole ionic liquid | 山西师范大学 | 2023-11-10 | — | — | CN | claimed |
| CN-117024364-A | Pyrazole ionic liquid and method for catalyzing Betti reaction by using pyrazole ionic liquid | 山西师范大学 | 2023-11-10 | — | — | CN | disclosed |
| US-11638706-B2 | Methods for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2023-05-02 | — | — | US | disclosed |
| EP-3638318-A1 | METHODS FOR MODIFYING RNA SPLICING | PTC Therapeutics, Inc. (US) | 2020-04-22 | — | — | EP | disclosed |
| WO-2018232039-A1 | METHODS FOR MODIFYING RNA SPLICING | PTC THERAPEUTICS, INC. (US) | 2018-12-20 | — | — | WO | disclosed |
| EP-3386511-A1 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2018-10-17 | — | — | EP | disclosed |
| WO-2017100726-A1 | METHODS FOR TREATNG HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. (US) | 2017-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11638706-B2 | Methods for treating Huntington's disease | HTT, HYPK, FH | MAPT 16/4885KDM4E 3361/4885ALDH1A1 1311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.